# Trial for Treatment Refractory Trigeminal Neuralgia

> **NCT03941834** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 65 (actual)

## Conditions studied

- Trigeminal Neuralgia

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03941834
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-25
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941834, "Trial for Treatment Refractory Trigeminal Neuralgia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03941834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*